MARA Holdings
MARA
Ecopetrol
EC
Oracle
ORCL
NVIDIA
NVDA
Apple
AAPL
US Stock MarketDetailed Quotes
NCNA NuCana
- 0.8900
- -0.0588-6.20%
Close Mar 7 16:00 ET
- 0.8900
- 0.00000.00%
Post 16:36 ET
3.49MMarket Cap-0.06P/E (TTM)
0.9680High0.8851Low9.81KVolume0.9200Open0.9488Pre Close9.01KTurnover0.29%Turnover RatioLossP/E (Static)3.93MShares19.410052wk High0.62P/B3.01MFloat Cap0.850052wk Low--Dividend TTM3.38MShs Float800.0000Historical High--Div YieldTTM8.74%Amplitude0.8500Historical Low0.9180Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
NuCana Stock Forum
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
7. I DO NOT give buy or sell advice
8. CH (cash on hand); AH (after hours): RTH (regular trading hours)
9. No buy pressure/momentum- No day trade.
10. Remember, some stocks may get pumped WITHOUT any catalyst this week ...
550% CTB loading 1.5 too 1.6
EDINBURGH, United Kingdom, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors (Module 1) and in combination with docetaxel for patients with lun...
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
NuCana announced initial data from its Phase 1b/2 study of NUC-3373 in combination therapies. In Module 1, combining NUC-3373 with pembrolizumab showed promising results in 12 advanced solid tumor patients, achieving a 22% objective response rate and 67% disease control rate. Notable cases included a bladder cancer patient achieving 100% target ...
No comment yet